Teva-Handok names Yoo Suk Hong as Chief Executive Officer
Posted: 8 April 2013 | | No comments yet
Teva-Handok announced the appointment of Yoo Suk Hong as the first Chief Executive Officer of the business venture…
Teva-Handok today announced the appointment of Yoo Suk Hong as the first Chief Executive Officer of the business venture established between Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Handok Pharmaceuticals (KRX: 002390). This business venture was formed in February, 2013 and focuses on the Korean pharmaceutical market, currently valued at approximately USD 14 billion.
“As we prepare to officially launch Teva-Handok, we are very pleased to welcome Yoo Suk Hong as our CEO,” stated Prof. Itzhak Krinsky, Chairman of Teva Japan, Chairman of Teva South Korea and Head of Business Development Asia Pacific. “With his deep international experience coupled with his keen understanding of the Korean market, Yoo Suk will help us realize our goal of bringing high-quality and affordable medicines to patients in Korea.”
Handok Pharmaceutical’s Chairman and CEO Young Jin Kim stated, “CEO Yoo Suk Hong has had a variety of work experiences in both Lilly headquarter and Korea with remarkable achievements. I believe with his competencies developed through global leadership, he will help establish Teva Handok as a leader in the Korean market.”
Teva-Handok is expected to officially launch its first products in September 2013.
